Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001034596) PYRROLECARBONYLIMINO DERIVATIVES AS NAALADASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/034596 International Application No.: PCT/US2000/030977
Publication Date: 17.05.2001 International Filing Date: 13.11.2000
IPC:
C07D 207/34 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
207
Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
30
having two double bonds between ring members or between ring members and non-ring members
34
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Applicants:
GUILFORD PHARMACEUTICALS INC. [US/US]; Linck, Nancy, J. Intellectual Property Department 6611 Tributary Street Baltimore, MD 21224, US
Inventors:
JACKSON, Paul, F.; US
SLUSHER, Barbara, S.; US
Agent:
CHONG, Suet, M.; Lyon & Lyon LLP 633 West Fifth Street Suite 4700 Los Angeles, CA 90071-2066, US
Priority Data:
09/438,97012.11.1999US
Title (EN) PYRROLECARBONYLIMINO DERIVATIVES AS NAALADASE INHIBITORS
(FR) DERIVES DE PYRROLECARBONYLIMINO UTILISES COMME INHIBITEURS DE LA NAALADase
Abstract:
(EN) The present invention relates to pharmaceutical compositions and methods of using pyrrolecarbonylimino derivatives to inhibit N-Acetylated $g(a)-Linked Acidic Dipeptidase (NAALADase) enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases and cancers.
(FR) L'invention concerne des compositions pharmaceutiques et des méthodes d'utilisation de dérivés de pyrrolecarbonylimino afin d'inhiber l'activité de l'enzyme NAALADase. Cette méthode permet de déclencher les activités neuronales; d'inhiber l'angiogénèse; et de traiter les anomalies liées au glutamate, les troubles compulsifs, les maladies et les cancers de la prostate.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)